PROTEIN SCIENCES ANNOUNCES LICENSING OF FLUBLOK TO UMN PHARMA FOR THE JAPAN MARKET

Protein Sciences Corporation (PSC) announced that it signed an agreement with UMN Pharma Inc., an entrepreneurial Japanese company (UMN), licensing FluBlOk, PSC's patented recombinant influenza vaccine, for the Japan market. PSC will transfer technology to UMN, which will be responsible for the registration, manufacture, marketing and sale of FluBlOk in Japan. Applications include annual and pandemic use of FluBlOk. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=28593&full=1)